Absci said interim Phase 1/2a data showed ABS-201 had a favorable preliminary safety profile in pattern hair loss, an early clinical signal for its lead dermato

BWB News TV • 2026-08-14 14:46 UTC • By Billy Odell Tucker-Robinson

Absci said interim Phase 1/2a data showed ABS-201 had a favorable preliminary safety profile in pattern hair loss, an early clinical signal for its lead dermatology candidate. More trial data are expected as development continues.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly